CardieX Ltd (ASX:CDX)'s ATCOR subsidiary has kicked off a new global clinical trial services agreement with Andwin Scientific.
The agreement is to lease ATCOR XCEL devices to Syneos Health and Philip Morris and to provide data management services for a new clinical trial sponsored by the tobacco giant.
Arterial health outcomes
The company’s ATCOR XCEL device is to be used in multiple endpoints for the trial, including determination of clinically relevant arterial health outcomes based on aortic augmentation index (AIx) and arterial stiffness, two key biomarkers of arterial health that are identified using the ATCOR XCEL device.
The trial will be run by clinical research organisation Syneos Health, with equipment from Andwin Scientific including the leased ATCOR XCEL from the CardieX holding.
The study is planned to continue for 19 months across 22 sites worldwide. The duration is based on expectations of the time required to enrol the subjects, conduct the study and analyse the results. Any extension in the length of the trial or expansion in the number of sites will increase the expected revenue flowing to CardieX.
The company plans to provide further updates on the trial once it has confirmed the registered details with Andwin.
About the ATCOR XCEL Device
ATCOR’s XCEL device is the only FDA-cleared device for non-invasively measuring central aortic waveforms and reporting on associated clinical data in all adult subjects.
XCEL is used by clinicians, research institutions and leading pharmaceutical companies to monitor critical hemodynamic data during patient treatment and drug trials in multiple clinical settings and for multiple disease states.
“We continue to see validation of our industry-leading SphygmoCor® technology globally with multiple on-going clinical trials relying on our XCEL device for advanced medical-grade arterial health parameters,” CEO and managing director Craig Cooper said.
“It’s this same technology that also powers our next generation of devices and partnerships with the upcoming Mobvoi smartwatch, as well as multiple new proposed devices in development for 2022.”